BCG-associated heterologous immunity, a historical perspective: Intervention studies in animal models of infectious diseases

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 109, Issue 1, 2014, Pages 52-61

  Freyne, Bridget ^a,b,c   Marchant, Arnaud ^d   Curtis, Nigel ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Animal; BCG; Heterologous; Non specific; Vaccine

Indexed keywords

BCG VACCINE;

ANIMAL MODEL; ARTICLE; BCG VACCINATION; CYTOKINE PRODUCTION; EXPERIMENTAL INFECTION; HETEROLOGOUS IMMUNITY; INNATE IMMUNITY; INTERVENTION STUDY; LYMPHOID CELL; MACROPHAGE ACTIVATION; NONHUMAN; RETICULOENDOTHELIAL SYSTEM; ADVISORY COMMITTEE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HISTORY; HUMAN; IMMUNOLOGY; MYCOBACTERIUM BOVIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUBERCULOSIS;

ANIMALIA;

ADVISORY COMMITTEES; ANIMALS; BCG VACCINE; DISEASE MODELS, ANIMAL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNITY, HETEROLOGOUS; INTERVENTION STUDIES; MYCOBACTERIUM BOVIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUBERCULOSIS;

EID: 84928897457     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/tru197     Document Type: Article

References (29)

1. Freyne B, Marchant A, Curtis N. BCG-associated heterologous immunity, a historical perspective: experimental models and immunological mechanisms. Trans R Soc Trop Med Hyg 2015;109:46-51.
2. Kilkenny C, Browne WJ, Cuthill IC et al. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010;8:e1000412.
3. Hirst JA, Howick J, Aronson JK et al. The need for randomization in animal trials: an overview of systematic reviews. PLoS One 2014;9:e98856.
4. Sena ES, van der Worp HB, Bath PM et al. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 2010;8:e1000344.
5. Tsilidis KK, Panagiotou OA, Sena ES et al. Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol 2013;11:e1001609.
6. Dubos RJ, Schaedler RW. Effects of cellular constituents of mycobacteria on the resistance of mice to heterologous infections I. Protective effects. J Exp Med 1957;106:703-17.
7. Howard JG, Biozzi G, Halpern AC et al. The effect of mycobacterium tuberculosis (BCG) infection on the resistance of mice to bacterial endotoxin and salmonella enteritidis infection. Cliniqye Medicale Propedeutique d l'Hopital Broussais; 1959.
8. Sher NA, Chaparas SD, Greenberg LE, Bernard S. Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice. Infect Immun 1975;12:1325-30.
9. Fagelman KM, Flint LM Jr, McCoy MT et al. Simulated surgical wound infection in mice: effect of stimulation on nonspecific host defense mechanisms. Arch Surg 1981;116:761-4.
10. Ortiz-Ortiz L, Gonzalez-Mendoza A, Lamoyi E. A vaccination procedure against Trypanosoma cruzi infection in mice by nonspecific immunization. J Immunol 1975;114:1424-5.
11. Kuhn RE, Vaughn RT, Herbst GA. The effect of BCG on the course of experimental Chagas' disease in mice. Int J Parasitol 1975;5:557-60.
12. Tabbara KJ, O'Connor GR, Nozik RA. Effect of immunization with attenuated Mycobacterium bovis on experimental toxoplasmic retinochoroiditis. Am J Ophthalmol 1975;79:641-7.
13. Civil RH, Warren KS, Mahmoud AA. Conditions for bacille Calmette-Guerin-induced resistance to infection with Schistosoma mansoni in mice. J Infect Dis 1978;137:550-5.
14. Hoff R. Killing in vitro of Trypanosoma cruzi by macrophages from mice immunized with T. cruzi or BCG, and absence of cross-immunity on challege in vivo. J Exp Med 1975;142:299-311.
15. van 't Wout JW, Poell R, van Furth R. The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand J Immunol 1992;36:713-9.
16. Werner GT. The effect of BCG-vaccination on vaccinia virus infections in mice. Experientia 1979;35:1514-5.
17. Larson CL, Ushijima RN, Karim R et al. Herpesvirus hominis type 2 infections in rabbits: effect of prior immunization with attenuated Mycobacterium bovis (BCG) cells. Infect Immun 1972;6:465-8.
18. Bell JF, Lodmell DL, Moore GJ, Raymond GH. Brain neutralization of rabies virus to distinguish recovered animals from previously vaccinated animals. J Immunol 1966;97:747-53.
19. Mackaness GB. The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med 1969;129:973-92.
20. Nakamura M, Cross WR. Susceptibility of rabbits immunized with Mycobacterium bovis (BCG) or Mycobacterium phlei to Shigella keratoconjunctivitis. Infect Immun 1972;6:1025-30.
21. Smrkovski LL, Larson CL. Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infect Immun 1977;16:249-57.
22. Salvin SB, Nishio J. Cellular origin of migration inhibitory factor released into the circulation of intact tuberculous mice. Federation Proceedings 1975;34:4355.
23. Salvin SB, Youngner JS, Nishio J, Neta R. Discussion paper: a tumor-inhibiting lymphokine from tuberculous mice. Ann NY Acad Sci 1976;276:369-72.
24. Salvin SB, Nishio J, Shonnard JT. Two new inhibitory activities in blood of mice with delayed hypersensitivity, after challenge with specific antigen. Infect Immun 1974;9:631-5.
25. Clark IA, Allison AC, Cox FE. Protection of mice against Babesia and Plasmodium with BCG. Nature 1976;259:309-11.
26. Suenaga T, Okuyama T, Yoshida I, Azuma M. Effect of Mycobacterium tuberculosis BCG infection on the resistance of mice to ectromelia virus infection: participation of interferon in enhanced resistance. Infect Immun 1978;20:312-4.
27. Sakuma T, Suenaga T, Yoshida I, Azuma M. Mechanisms of enhanced resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus infection. Infect Immun 1983;42:567-73.
28. Kleinnijenhuis J, Quintin J, Preijers F et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 2012;109:17537-42.
29. Parra M, Liu X, Derrick SC et al. Molecular analysis of non-specific protection against murine malaria induced by BCG vaccination. PLoS One 2013;8:e66115.